Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/7899
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoldwater, P.-
dc.date.issued1997-
dc.identifier.citationVaccine, 1997; 15(4):353-356-
dc.identifier.issn0264-410X-
dc.identifier.issn1873-2518-
dc.identifier.urihttp://hdl.handle.net/2440/7899-
dc.description.abstractFifty-two adults who had previously received 4 x 20 micrograms doses of hepatitis B [Engerix-B] vaccine (appropriately administered into the deltoid muscle) and who had failed to develop detectable anti-HBs were randomized to receive a fifth dose of Engerix-B (either 20 micrograms or 40 micrograms) intramuscularly (deltoid). The participants were blinded as to the contents of the syringe. Anti-HBs was tested (by EIA) 3 months after the injection. Anti-HBs results from 45 non-responders were evaluable. Seven vaccinees were excluded; four of these on the basis of failure to have follow-up blood collected and three who were found to be anti-HBc positive (one HBsAg positive). Twelve of 22 (54.5%) of those receiving 20 micrograms of HB vaccine developed anti-HBs, whereas 10 of 23 (43.5%) who received 40 micrograms developed anti-HBs, showing no significant difference between the regimens. The mean geometric titres were 93 +/- 50 and 86 +/- 51 IU l-1, respectively. Vaccinee groups were well matched for age, sex and body mass index and the interval between injection and bleeding. Side-effects in those receiving the double (40 micrograms) dose were no different from those receiving the normal (20 micrograms) adult dose. On the basis of this study, a fifth dose of vaccine in non-responsive vaccinees is recommended. No significant advantage of 40 micrograms over 20 micrograms of vaccine was observed. Whilst smoking and obesity were common in this cohort of non-responders and probably contributed to the individuals primary non-responsive state, these factors had no unfavourable effect on response to a fifth dose of vaccine.-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.source.urihttp://dx.doi.org/10.1016/s0264-410x(96)00202-2-
dc.subjectHumans-
dc.subjectHepatitis B-
dc.subjectVaccines, Synthetic-
dc.subjectHepatitis B Vaccines-
dc.subjectHepatitis B Antibodies-
dc.subjectBody Mass Index-
dc.subjectTreatment Failure-
dc.subjectImmunization, Secondary-
dc.subjectInjections, Intramuscular-
dc.subjectDrug Administration Schedule-
dc.subjectCase-Control Studies-
dc.subjectFollow-Up Studies-
dc.subjectAdolescent-
dc.subjectAdult-
dc.subjectMiddle Aged-
dc.subjectFemale-
dc.subjectMale-
dc.titleRandomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders-
dc.typeJournal article-
dc.identifier.doi10.1016/S0264-410X(96)00202-2-
pubs.publication-statusPublished-
dc.identifier.orcidGoldwater, P. [0000-0003-4822-8488]-
Appears in Collections:Aurora harvest
Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.